证券代码：833230 证券简称：欧康医药 公告编号：2023-074 成都欧康医药股份有限公司 关于拟修订《公司章程》公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 一、修订内容 根据《公司法》、《上市公司章程指引（2022 年修订）》、《上市公司独立董事 管理办法》、《北京证券交易所股票上市规则（试行）》、《北京证券交易所上市公 司持续监管指引第 1 号—独立董事》等相关规定，公司拟修订《公司章程》的部 分条款，修订对照如下： | 原规定 | 修订后 | | --- | --- | | 第一条 为维护公司、公司股东和债权 | 第一条 为维护成都欧康医药股份有 | | 人的合法权益，规范公司的组织和行 | 限公司（以下简称"公司"）及其股东 | | 为，根据《中华人民共和国公司法》（以 | 和债权人的合法权益，规范公司的组织 | | 下简称"《公司法》"）、《中华人民共和 | 和行为，根据《中华人民共和国公司法》 | | 国证券法》（以下简称"《证券法》"）、《北 | （以下简称"《公司法》"） ...

证券代码：833230 证券简称：欧康医药 公告编号：2023-091 成都欧康医药股份有限公司董事会秘书工作细则 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 一、 审议及表决情况 成都欧康医药股份有限公司于 2023 年 11 月 14 日召开了第三届董事会第二 十二次会议，审议通过《关于修订<董事会秘书工作细则>的议案》，本议案无需 提交股东大会审议。表决结果：同意 9 票，反对 0 票，弃权 0 票。 第二条 公司设董事会秘书一名，董事会秘书为公司高级管理人员，对公司 和董事会负责。 第三条 董事会秘书应当具备履行职责所必需的财务、管理、法律专业知识， 具有良好的职业道德和个人品德。 第四条 董事会秘书候选人除应当符合董事、监事、高级管理人员的任职条 件外，同时不得存在下列任一情形： （一）存在《公司法》第一百四十六条规定情形之一的； （二）被中国证券监督管理委员会（以下简称"中国证监会"）及其派出机 构采取证券市场禁入措施或者认定为不适当人选，期限尚未届满的； 二、 制度的主要内容，分章节列 ...

证券代码：833230 证券简称：欧康医药 公告编号：2023-077 成都欧康医药股份有限公司于 2023 年 11 月 14 日召开了第三届董事会第二 十二次会议，审议通过《关于制定<独立董事专门会议工作制度>的议案》，本议 案无需提交股东大会审议。表决结果：同意 9 票，反对 0 票，弃权 0 票。 二、 制度的主要内容，分章节列示： 成都欧康医药股份有限公司 独立董事专门会议工作制度 成都欧康医药股份有限公司独立董事专门会议工作制度 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 一、 审议及表决情况 第一条 为完善公司法人治理结构，促进成都欧康医药股份有限公司（以 下简称"公司"）规范运作，维护公司整体利益，有效保障全体股东、特别是 中小股东的合法权益不受损害，根据《中华人民共和国公司法》（以下简称"《公 司法》"）、《中华人民共和国证券法》（以下简称"《证券法》"）、《北京证券交易 所上市公司持续监管办法（试行）》、《北京证券交易所股票上市规则（试行）》 （以下简称"《上市规则》"）、《北京 ...

| 日期 | 代码 | 简称 | 成交价 | 成交数量（股） | 买入营业部 | 卖出营业部 | | --- | --- | --- | --- | --- | --- | --- | | 2023-11- | | | | | 中信证券股份有限公 | 国泰君安证券股份有 | | 09 | 832469 | 富恒新材 | 4.9 | 210000 | 司天津黄河道证券营 | 限公司江苏南京太平 | | | | | | | 业部 | 南路营业部 | | 2023-11- | | | | | 国泰君安证券股份有 | 国泰君安证券股份有 | | 09 | 832982 | 锦波生物 | 189 | 80000 | 限公司湖南益阳益阳 | 限公司湖南益阳益阳 | | | | | | | 大道营业部 | 大道营业部 | | 2023-11- | | | | | 宏信证券有限责任公 | 申万宏源证券有限公 | | 09 | 833230 | 欧康医药 | 7 | 101000 | 司成都一环路西二段 | 司成都温江南江路证 | | | | | | | 营业部1 | 券营业部 | | 2023-11- | | | | | 中 ...

本公司及监事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 一、会议召开和出席情况 （一）会议召开情况 证券代码：833230 证券简称：欧康医药 公告编号：2023-073 成都欧康医药股份有限公司 第三届监事会第十九次会议决议公告 5.会议主持人：监事会主席韩英 6.召开情况合法、合规、合章程性说明： 本次会议的召集、召开和议案审议程序等符合有关法律、行政法规、部门规 章等规范性文件，符合《公司法》、《公司章程》的有关规定。 （二）会议出席情况 会议应出席监事 3 人，出席和授权出席监事 3 人。 监事侯霞莉因工作原因以通讯方式参与表决。 二、议案审议情况 （一）审议通过《关于审议<2023 年第三季度报告>的议案》 1.议案内容： 根据《公司法》、《证券法》、《北京证券交易所上市公司持续监管指引第 2 号——季度报告》的规定，公司组织编制了《成都欧康医药股份有限公司 2023 1.会议召开时间：2023 年 10 月 27 日 2.会议召开地点：公司会议室 3.会议召开方式：现场结合通讯方式 4.发出监事会会 ...

证券代码：833230 证券简称：欧康医药 公告编号：2023-072 成都欧康医药股份有限公司 7.召开情况合法、合规、合章程性说明： 第三届董事会第二十一次会议决议公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 一、会议召开和出席情况 （一）会议召开情况 1.会议召开时间：2023 年 10 月 27 日 2.会议召开地点：公司会议室 3.会议召开方式：现场结合通讯方式 4.发出董事会会议通知的时间和方式：2023 年 10 月 20 日以通讯方式发出 5.会议主持人：董事长赵卓君 6.会议列席人员：全体监事、高级管理人员 本次会议的召集、召开和议案审议程序等符合有关法律、行政法规、部门规 章等规范性文件，符合《公司法》、《公司章程》的有关规定。 （二）会议出席情况 会议应出席董事 9 人，出席和授权出席董事 9 人。 董事赵卓君、伍丽因工作出差以通讯方式参与表决。 二、议案审议情况 （一）审议通过《关于审议<2023 年第三季度报告>的议案》 1.议案内容： 根据《公司法》、《证券法》、《北 ...

Financial Performance - Net profit attributable to shareholders for the first nine months of 2023 was CNY 12,660,076.62, down 56.18% year-on-year[11]. - Operating revenue for the first nine months of 2023 was CNY 169,781,662.69, representing an 18.91% decline compared to the same period in 2022[11]. - The company's basic earnings per share for the first nine months of 2023 was CNY 0.17, down 66.00% from CNY 0.50 in the previous year[11]. - The company's net profit decreased by 56.18% year-on-year, primarily due to weakened overseas market consumption and increased competition leading to price reductions in the market[14]. - Total operating revenue for the first nine months of 2023 was CNY 169,781,662.69, a decrease from CNY 209,370,432.49 in the same period of 2022, representing a decline of approximately 19%[40]. - Net profit for the first nine months of 2023 was CNY 12,660,076.62, compared to CNY 28,892,943.00 in 2022, reflecting a decrease of approximately 56%[41]. - The total comprehensive income attributable to shareholders was ¥12,660,076.62, down from ¥28,892,943.00, a decline of approximately 56.1%[42]. Cash Flow - The net cash flow from operating activities for the first nine months of 2023 was CNY 17,230,872.40, a decrease of 70.73% year-on-year[11]. - Cash flow from operating activities decreased by 70.73% compared to the same period last year, mainly due to reduced operating income and increased prepaid payments[14]. - The net cash flow from operating activities for the first nine months of 2023 was ¥8,864,133.06, a decrease of 85.2% compared to ¥60,028,342.34 in the same period of 2022[51]. - Cash inflow from operating activities totaled ¥206,878,871.97, down 11.5% from ¥233,765,683.74 year-on-year[51]. - Cash outflow from operating activities increased to ¥198,014,738.91, compared to ¥173,737,341.40 in the previous year, marking a rise of 13.9%[51]. Assets and Liabilities - Total assets as of September 30, 2023, were CNY 420,027,274.92, a decrease of 4.64% compared to the end of 2022[11]. - The total liabilities to total assets ratio (consolidated) was 7.53% as of September 30, 2023, compared to 11.40% at the end of 2022[11]. - The company's current liabilities as of September 30, 2023, total CNY 28,877,363.24, down from CNY 47,237,795.01 at the end of 2022[33]. - Total liabilities as of September 30, 2023, were CNY 31,585,766.19, a decrease from CNY 47,311,962.83 at the end of 2022, representing a reduction of about 33%[38]. - Total equity attributable to shareholders was CNY 387,888,413.60 as of September 30, 2023, compared to CNY 389,977,582.80 at the end of 2022, showing a slight decrease[38]. Investments and Income - Investment income for the first nine months of 2023 increased by 2,797.82% year-on-year, attributed to increased investment in financial products[13]. - Other income decreased by 55.75% year-on-year, mainly due to a reduction in government subsidies received[13]. - The company reported a 67.24% increase in asset disposal income, attributed to the sale of non-applicable fixed assets[14]. - The company's investment activities generated a net cash outflow of 39,798,265.70 yuan, a decrease of 13.64% year-on-year, due to increased fixed asset investments[14]. Shareholder Information - The total number of ordinary shares outstanding remained at 75,631,404, with 75% being restricted shares[19]. - Major shareholders include Zhao Zhuojun with 41.22% and Wu Li with 27.43% of the total shares[21]. Operational Developments - The company obtained a new food production license, increasing its product offerings from 3 to 8, enhancing its market competitiveness[27]. - The company’s raw material "Diosmin" passed GMP compliance checks, allowing it to expand its domestic raw material market[27]. - The company is advancing its project for the expansion of Chengdu Okang Pharmaceutical Co., Ltd., currently in the equipment installation and decoration phase[28]. - The company received acceptance for the listing of citrus flavonoid raw materials, marking a significant step in its domestic market strategy[28]. Future Outlook - The company anticipates a better industry development order as some manufacturers exit the market[14]. - The net cash flow from financing activities reflects the company's strategy to manage its capital structure amid market challenges[15].

证券代码：833230 证券简称：欧康医药 公告编号：2023-070 成都欧康医药股份有限公司 关于公司食品生产许可证变更的公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记 载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个 别及连带法律责任。 成都欧康医药股份有限公司（以下简称"公司"）于近日取得成都市市场监 督管理局颁发的《食品生产许可证》，同意公司《食品生产许可证》的变更申请。 本次变更主要涉及新增 5 个产品的生产，其他内容不变。具体情况如下： 一、变更后的《食品生产许可证》基本情况 生产者名称：成都欧康医药股份有限公司 统一社会信用代码：91510100698888960C 法定代表人（负责人）：赵卓君 住所：邛崃市临邛工业园区创业路 15 号 生产地址：邛崃市临邛工业园区创业路 15 号 食品类别：食品添加剂，蛋制品 许可证编号：SC20151018350046 有效期至：2028 年 9 月 13 日 发证机关：成都市市场监督管理局 二、对公司的影响 本次变更《食品生产许可证》是在原有的"新甲基橙皮苷二氢查耳酮、柚苷、 L-鼠李糖"3 个食品添加剂类产品 ...

成都欧康医药股份有限公司 关于分公司完成工商登记并取得营业执照的公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记 载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个 别及连带法律责任。 证券代码：833230 证券简称：欧康医药 公告编号：2023-069 1、名称：成都欧康医药股份有限公司羟基芦丁分公司 证件为准） 一般项目：食品添加剂销售；专用化学产品销售（不含危险化学 品）；医学研究和试验发展；信息咨询服务（不含许可类信息咨询服务）；技术服 务、技术开发、技术咨询、技术交流、技术转让、技术推广；技术进出口；货物 进出口；农业科学研究和试验发展。（除依法须批准的项目外，凭营业执照依法 自主开展经营活动） 一、基本情况 成都欧康医药股份有限公司（以下简称"公司"）于 2023 年 8 月 22 日召开 第三届董事会第二十次会议，审议通过了《关于设立分公司的议案》。公司于 2023 年 8 月 22 日在北京证券交易所网站（www.bse.cn）进行了披露。详见《成都欧 康医药股份有限公司第三届董事会第二十次会议决议公告》（公告编号：2023- 064）、《成都欧康医药 ...

Financial Performance - In the first half of 2023, the company's operating revenue was ¥112,225,810.15, a decrease of 27.01% compared to ¥153,751,776.79 in the same period last year[27]. - The gross profit margin for the first half of 2023 was 18.13%, down from 28.18% in the previous year[27]. - The net profit attributable to shareholders of the listed company was ¥10,245,890.81, representing a decline of 60.98% from ¥26,257,163.71 in the same period last year[27]. - The net profit after deducting non-recurring gains and losses was ¥8,889,919.72, down 64.40% from ¥24,973,970.37 year-on-year[27]. - The weighted average return on net assets based on net profit attributable to shareholders was 2.61%, a decrease from 16.72% in the previous year[27]. - Operating cash flow decreased by 26.90% to ¥32,148,479.36 from ¥43,976,719.02 year-over-year[29]. - Net profit decreased by 60.98% compared to the same period last year[30]. - The company achieved a net non-recurring profit of ¥1,355,971.09 after tax[32]. - The company reported a 216.13% increase in revenue from rutin and a 178.89% increase in revenue from berberine, contributing to overall profit growth[41]. - The company’s external sales revenue grew by 6.39% year-on-year, while internal sales revenue fell by 35.86%[66]. Assets and Liabilities - Total assets decreased by 3.23% to ¥426,252,902.73 from ¥440,473,318.89 year-over-year[28]. - Total liabilities decreased by 18.96% to ¥40,703,541.34 from ¥50,225,567.49 year-over-year[28]. - The company's cash and cash equivalents decreased by 38.52% to 118,479,830.62 CNY, primarily due to cash payments for project construction and bank loan repayments[54]. - Accounts receivable decreased by 39.67% to 36,407,318.76 CNY, attributed to improved customer credit management strategies[54]. - The company's construction in progress increased by 308.25% to 51,234,431.25 CNY, reflecting significant investment in project upgrades and expansions[54]. - The total current assets decreased from CNY 378,983,354.45 as of December 31, 2022, to CNY 320,567,537.36 as of June 30, 2023, representing a decline of approximately 15.4%[120]. - The total non-current assets increased from CNY 61,489,964.44 as of December 31, 2022, to CNY 105,685,365.37 as of June 30, 2023, indicating an increase of approximately 71.8%[122]. - The total liabilities decreased from CNY 50,225,567.49 as of December 31, 2022, to CNY 40,703,541.34 as of June 30, 2023, reflecting a reduction of about 19.0%[123]. Investments and Fundraising - The company is actively advancing its fundraising projects, with the "Chengdu Okay Pharmaceutical Co., Ltd. Technical Transformation and Expansion Project (Phase I)" progressing smoothly according to plan[7]. - The company has invested an additional ¥35 million in fundraising projects to improve product quality and production efficiency[36]. - The company raised a total of RMB 231,500,556.80 from the public offering of shares, with a net amount of RMB 212,317,682.73 after deducting issuance costs[105]. - As of June 30, 2023, the cumulative investment in fundraising projects amounted to RMB 135,762,100, with RMB 101,566,700 used during the reporting period[106]. - The balance of the fundraising account as of June 30, 2023, was RMB 79,961,000[106]. Research and Development - The company has obtained two invention patents, bringing the total number of patents to 36 as of the report date[5]. - The company has obtained two invention patents related to the preparation processes of flavonoids, enhancing its competitive edge in cost reduction and innovation[37]. - R&D expenses increased by 13.37% due to heightened investment in innovation, while management, financial, and sales expenses were reduced by 17.55%, 183.55%, and 5.79% respectively[44]. - The company is focusing on research and development of new products and improving production processes to enhance competitiveness[84]. Market Expansion and Strategy - The company established a foreign holding subsidiary, OKAYPHARM USA INC., in Los Angeles to expand into the health product market[8]. - The company plans to expand its product applications in domestic markets, including functional food ingredients and cosmetics, while also developing a health product brand in the U.S. using quercetin[43]. - The company is investing in an automated workshop and digital factory to enhance production efficiency and reduce costs for its products[42]. - The company is actively developing domestic raw materials and functional food markets to mitigate risks from international trade environments[80]. - The company is focused on expanding its market presence both domestically and internationally to achieve a dual-market strategy[80]. Compliance and Certifications - The company has passed multiple quality certifications including EuGMP, FSSC22000, HACCP22000, ISO9001, HALAL, and KOSHER, which are crucial for maintaining market access[80]. - The company has obtained the Pollution Discharge Permit from the Chengdu Ecological Environment Bureau, valid from December 22, 2020, to December 21, 2025[78]. - The company has established an EHS management system to oversee environmental protection and pollution control during production[78]. Shareholder Information - The total number of ordinary shares at the end of the period is 75,631,404, with 25% being unrestricted shares after the conversion of 3,202,320 restricted shares[99][100]. - Major shareholders include Zhao Zhuojun with 31,178,881 shares (41.22%) and Wu Li with 20,748,000 shares (27.43%) at the end of the reporting period[103]. - The total shares held by directors and supervisors amount to 53,370,830, which is 70.55% of the total shares[113]. - The company has not issued any preferred shares or convertible bonds during the reporting period[108]. Financial Management - The company has provided guarantees totaling ¥10,000,000 for loans at both Agricultural Bank of China and China Merchants Bank, with a guarantee period from February 2023 to February 2025[91]. - The company has also guaranteed ¥5,000,000 for a loan at Industrial and Commercial Bank of China, with a guarantee period from June 2023 to June 2024[91]. - The company has completed the repayment of all mortgage loans from Bank of China by June 30, 2023, although the asset release procedures are still pending[96]. Operational Changes - The company has established a comprehensive employee welfare system to ensure fair and healthy working conditions[77]. - The company appointed a new supervisor, Li Hua, due to the resignation of Wei Liuli, ensuring compliance with the legal minimum number of supervisory board members[115]. - The number of total employees increased from 208 at the beginning of the period to 210 at the end of the period, with a net addition of 2 employees[117]. - The number of technical personnel increased from 43 to 46, showing a growth of approximately 7.0%[117].